Spectranetics Corp  

(Public, NASDAQ:SPNC)   Watch this stock  
Find more results for The Spectranetics Corp
28.05
+1.50 (5.65%)
After Hours: 28.05 0.00 (0.00%)
Feb 24, 4:21PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 26.95 - 28.60
52 week 12.59 - 28.60
Open 27.50
Vol / Avg. 849,905.00/319,351.00
Mkt cap 1.20B
P/E     -
Div/yield     -
EPS -1.31
Shares 43.20M
Beta 1.64
Inst. own 95%
Feb 23, 2017
Q4 2016 Spectranetics Corp Earnings Release (Estimated)
Jan 11, 2017
Spectranetics Corp at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -19.50% -24.18%
Operating margin -14.45% -31.04%
EBITD margin - -7.23%
Return on average assets -12.26% -12.72%
Return on average equity -61.67% -42.61%
Employees 892 -
CDP Score - -

Address

9965 Federal Dr
COLORADO SPRINGS, CO 80921-3822
United States - Map
+1-719-6338333 (Phone)
+1-877-4472022 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

The Spectranetics Corporation is a United States-based company, which develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are available in over 65 countries and are used to cross, prepare and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads. The Company's segments include U.S. Medical and International Medical. The U.S. Medical segment offers medical devices, including fiber-optic devices and non-fiber-optic products (disposables), an excimer laser system (equipment), and the service of the excimer laser system (service). The International Medical segment serves Europe, the Middle East, Asia Pacific, Latin America and Puerto Rico, and provides Stellarex DCB and AngioSculptX products, which are available for sale in Europe. The Company's solutions include Lead Management, Peripheral Intervention and Coronary Intervention.

Officers and directors

R. John Fletcher Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Scott William Drake President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Stacy McMahan Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Shahriar Matin Chief Operating Officer
Age: 40
Bio & Compensation  - Reuters
Paul Gardon Senior Vice President, General Counsel
Age: 49
Bio & Compensation  - Reuters
Donna Ford-Serbu Senior Vice President - Sales and Marketing of Lead Management
Age: 46
Bio & Compensation  - Reuters
Robert Michael Fuchs Senior Vice President, Global Head - Human Resources
Age: 48
Bio & Compensation  - Reuters
Udo Scheiner Senior Vice President - International Operations
Bio & Compensation  - Reuters
Austin B. Byrd Chief Compliance Officer, Vice President
Age: 49
Bio & Compensation  - Reuters
Wade A. Bowe Vice President - Research & Development
Age: 44
Bio & Compensation  - Reuters